The FDA reviewed risks and loosened the label on testosterone replacement therapy (TRT) following an attempt by the Trump administration to reverse its decline.
4 reports, 3 independent
Updated Mon 00:00
No new developments lately
- Reports
- 4
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA reviewed risks and loosened the label on testosterone replacement therapy (TRT) following an attempt by the Trump administration to reverse its decline.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Administration pushes for regulatory changes to TRT and defense secretary implements mandatory testosterone screening.1 source
- Policy views clash with scientific consensus on T therapy.Sub-event
FDA revises TRT labeling; Trump administration attempts to reverse testosterone decline.1 source
Keep exploring
The entities involved
- FDA
-
Testosterone
- Dorothy Fink, who serves as deputy director, is involved in research on testosterone at the Eunice Kennedy Shriver National Institute of Child Health and Human Development in Toronto.
- Pharmaceutical companies are producing testosterone replacement therapies, which are being touted as anti-aging treatments, while the U.S. military tests service members' levels.
-
Brian Christine
American physician-scientist (born 1960)
-
Department of Health & Human Services
government department in the state of Victoria, Australia